Last reviewed · How we verify
SNK01
At a glance
| Generic name | SNK01 |
|---|---|
| Sponsor | NKGen Biotech, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Open-Label Extension Protocol to SNK01-AD01 Study (PHASE2)
- Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease (PHASE1, PHASE2)
- Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers (PHASE1, PHASE2)
- Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD) (PHASE1)
- Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy (PHASE1)
- A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment (PHASE1, PHASE2)
- Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers (PHASE1, PHASE2)
- Autologous Natural Killer Cells in Subjects With Plaque Psoriasis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SNK01 CI brief — competitive landscape report
- SNK01 updates RSS · CI watch RSS
- NKGen Biotech, Inc. portfolio CI